Phase 4
Completed N=110
Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19
Source: ClinicalTrials.gov NCT04707534 ↗Enrolled (actual)
110
Serious AEs
2.8%
Results posted
Mar 2024
Primary outcomePrimary: Number of Participants With Clinical Improvement of Greater Than or Equal to 2 Points Using the WHO-OSCI at Day 28 — 37; 43 Participants
◆ Published Evidence
Established
43citations · ~11 / year
Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A randomized clinical trial.
Summary
This open label clinical trial is to evaluate two different doses of dexamethasone on the health outcome using World Health Organization ordinal scale at day 28 in hospitalized patients with COVID-19.
Linked Publications
-
Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A randomized clinical trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Clinical Improvement of Greater Than or Equal to 2 Points Using the WHO-OSCI at Day 28 |
37; 43 | — |
| SECONDARY 28-day Mortality |
11; 5 | — |
Eligibility Criteria
Inclusion Criteria
- Age ≥ 18 years old
- RT-PCR confirmed COVID-19 infection
- Positive pressure ventilation (non-invasive or invasive) or high flow nasal cannula (HFNC) or need supplemental oxygen with oxygen mask or nasal cannula
Exclusion Criteria
- Underlying disease requiring chronic corticosteroids
- Severe adverse events before admission, i.e. cardiac arrest;
- Contraindication for corticosteroids;
- Death is deemed to be imminent and inevitable during the next 24 hours
- Recruited in other clinical intervention trial
- Pregnancy
- Patient on judicial protection
Data sourced from ClinicalTrials.gov (NCT04707534) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.